BRYREL
Clinical safety rating: caution
Comprehensive clinical and safety monograph for BRYREL (BRYREL).
BRYREL (bryrelimab) is a monoclonal antibody that binds to the extracellular domain of the human epidermal growth factor receptor 2 (HER2), inhibiting downstream signaling pathways including PI3K/Akt and MAPK, leading to cell cycle arrest and apoptosis in HER2-overexpressing tumor cells. It also mediates antibody-dependent cellular cytotoxicity (ADCC).
| Metabolism | Metabolized by general protein catabolism; no specific metabolic enzymes identified. Elimination via reticuloendothelial system. |
| Excretion | Primarily renal excretion; 70% as unchanged drug via glomerular filtration and tubular secretion; 30% metabolized in liver to inactive metabolites, with 10% biliary excretion. |
| Half-life | Terminal half-life 6–8 hours in healthy adults; prolonged to 12–15 hours in moderate renal impairment (CrCl 30–50 mL/min) and up to 24 hours in severe impairment (CrCl <30 mL/min). |
| Protein binding | 45% bound to albumin; minor binding to α1-acid glycoprotein. |
| Volume of Distribution | 0.8 L/kg (total body water distribution); increased in heart failure (up to 1.2 L/kg) and cirrhosis. |
| Bioavailability | Oral: 75% (range 60–85%) |
| Onset of Action | Intravenous: 5–10 minutes; Oral: 30–60 minutes. |
| Duration of Action | 4–6 hours for intravenous route; 6–8 hours for oral route; extended in renal impairment. |
100 mg orally once daily, with or without food.
| Dosage form | SYRUP |
| Renal impairment | GFR 30-59 mL/min: 50 mg once daily; GFR <30 mL/min or on dialysis: 25 mg once daily. |
| Liver impairment | Child-Pugh class A: no adjustment; Child-Pugh class B: 50 mg once daily; Child-Pugh class C: not recommended. |
| Pediatric use | Not established for patients <18 years; safety and efficacy not evaluated. |
| Geriatric use | No dose adjustment required based on age alone; consider renal function for dosing. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for BRYREL (BRYREL).
| Breastfeeding | Brivaracetam is excreted in human breast milk. The milk-to-plasma (M/P) ratio is approximately 0.8. Limited data suggest infant serum levels are low, but systematic studies are lacking. Due to potential adverse effects in nursing infants (drowsiness, poor feeding), caution is advised. Manufacturer recommends discontinuing breastfeeding or the drug, considering the importance of the drug to the mother. |
| Teratogenic Risk | BRYREL (brivaracetam) is classified as FDA Pregnancy Category C. In animal studies, brivaracetam caused developmental toxicity (increased incidence of fetal malformations and embryofetal death) at maternal toxic doses. There are no adequate and well-controlled studies in pregnant women. First trimester exposure carries a potential risk of major congenital malformations, particularly neural tube defects and orofacial clefts, based on animal data and class effect of other antiepileptic drugs. Second and third trimester exposure may be associated with adverse neurodevelopmental outcomes. Use only if potential benefit justifies risk to fetus. |
■ FDA Black Box Warning
None
| Serious Effects |
Hypersensitivity to bryrelimab or any excipients. Severe uncontrolled hypertension. Clinically significant left ventricular ejection fraction (LVEF) reduction below 50% or below institutional lower limit of normal.
| Precautions | Cardiomyopathy: left ventricular dysfunction, congestive heart failure, risk increased with concurrent anthracyclines. Infusion reactions: dyspnea, hypotension, angioedema. Pulmonary toxicity: interstitial lung disease, pneumonitis. Embryo-fetal toxicity: oligohydramnios, fetal renal impairment. Exacerbation of chemotherapy-induced neutropenia. |
| Food/Dietary | Avoid dairy products (milk, yogurt, cheese), calcium-fortified foods, and high-calcium mineral water within 2 hours of dosing. Do not take with iron-rich foods or supplements. Grapefruit juice may increase doxycycline absorption; avoid concurrent intake. Alcohol is not contraindicated but may increase GI upset. |
Loading safety data…
| Fetal Monitoring | Monitor pregnant women for seizure frequency and therapeutic drug levels (brivaracetam levels may decrease due to pregnancy-induced pharmacokinetic changes). Fetal monitoring includes serial ultrasound for fetal growth and anatomy surveillance. Consider prenatal vitamin supplementation with folic acid (4 mg daily) prior to and during pregnancy to reduce neural tube defect risk. Postnatal monitoring of the neonate for signs of withdrawal (irritability, feeding difficulties, sedation) is recommended. |
| Fertility Effects | In animal studies, brivaracetam did not impair male or female fertility at clinically relevant doses. In humans, no significant effects on fertility have been reported. However, as with all antiepileptic drugs, underlying epilepsy itself may affect fertility. Caution is advised for women of childbearing potential regarding contraceptive use due to potential teratogenicity. |
| Clinical Pearls | BRYREL (doxycycline hyclate) is a tetracycline antibiotic with high oral bioavailability; administer with a full glass of water to reduce esophageal irritation. Avoid dairy products, antacids, iron, or bismuth subsalicylate within 2 hours of dosing due to chelation. Use sunscreen and protective clothing due to photosensitivity. Monitor for superinfection, especially candidiasis. In pediatric patients <8 years, contraindicated due to permanent tooth discoloration. |
| Patient Advice | Take exactly as prescribed; complete the full course even if you feel better. · Swallow capsule whole with plenty of water; do not crush or chew. · Avoid milk, yogurt, cheese, antacids, iron supplements, or bismuth subsalicylate within 2 hours before or after taking BRYREL. · Avoid prolonged sun exposure; use sunscreen and protective clothing; report severe sunburn-like reactions. · If you miss a dose, take it as soon as you remember unless it's near the time of the next dose; do not double the dose. · Contact your healthcare provider if you develop watery or bloody diarrhea, severe headache, blurred vision, or signs of liver problems (dark urine, yellowing skin/eyes). · Do not use if you are pregnant, planning to become pregnant, or breastfeeding unless directed by your doctor. · Store at room temperature away from moisture and heat; keep out of reach of children. |